ORYZON Genomics Appoints Greg Weaver As Global Chief Financial Officer

CAMBRIDGE, Massachusetts and BARCELONA, Spain, January 12, 2015 /PRNewswire/ --

Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, today announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015. Weaver brings more than 30 years of experience to Oryzon, including extensive financial and operational experience with publicly- and privately-held biotechnology companies. Weaver will report directly to Carlos Buesa, President and Chief Executive Officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA.

Weaver has served as CFO of several public biotech companies in the US, most recently Fibrocell Science. Previous to Fibrocell, Weaver was CFO at Celsion Corp, Poniard Pharmaceuticals and Sirna Therapeutics. He also currently serves as non executive director of Egalet Corporation (Nasdaq: EGLT) and Atossa Genetics (Nasdaq: ATOS).

"I am very pleased to welcome Greg to the Oryzon management team. I had the pleasure of working with Greg as a Director of Oryzon and have highly valued his contribution to the Company thus far. Greg brings a very strong skill set and experience base to Oryzon," said Carlos Buesa, President and Chief Executive Officer of Oryzon. "He is a highly experienced international CFO and his significant experience with US listed biotech companies will be very valuable to our executive team as we drive our strategic and financial business forward with particular focus on the US."

Commenting on his appointment, Mr. Weaver said: "This is a very exciting time to be joining Oryzon. The Company has made tremendous progress under Carlos Buesa's leadership. Oryzon is approaching several key inflection points that represent exciting opportunities for value creation. I look forward to working with this talented team to position the Company for its next phase of growth."

Weaver earned his MBA from Boston College Graduate School of Business, his BSc in Accounting from Trinity University, and his CPA was licensed in Texas and Massachusetts.

Oryzon's Mr. Enric Rello will remain as CFO in Spain and will continue as part of Oryzon's senior management team to support the Company's financial operations in Spain.

ORYZON closed, in April 2014, a global deal with ROCHE on its first asset, ORY-1001 a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA. Under the terms of the agreement, Oryzon received an upfront payment and near-term milestones totalling $21 million, plus potential development, commercial and sales milestone payments across haematology, cancer and non-malignant indications that could exceed $500 million, together with tiered royalties on sales which range up to mid-double digits. The company is expecting to move a second epigenetic molecule, ORY-2001 a dual LSD1-MAOB inhibitor for the treatment of neurodegenerative disorders, into clinic this year.


Founded in 2000 in Barcelona, Spain, Oryzon (http://www.oryzon.com) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolios in the field. Its LSD1 program is currently covered by 18 patent families. The company has also a strong technological platform for biomarker identification. The company performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. In October 2014, ORYZON announced the opening of U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.


Carlos Buesa

President & CEO
[email protected]
W: +34-93-515-1313

Greg Weaver
Executive V.P. and Global CFO
[email protected]
W: +1-617-444-8786

Tim Opler

Torreya Partners

Managing Partner

[email protected]
W: +1-212-331-7843

SOURCE Oryzon Genomics 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.